AU Patent

AU2013296627C9 — Deuterated ibrutinib

Assigned to Concert Pharmaceuticals Inc · Expires 2018-03-22 · 8y expired

What this patent protects

The present invention in one embodiment provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula (I) are as defined in the specification.

USPTO Abstract

The present invention in one embodiment provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula (I) are as defined in the specification.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013296627C9
Jurisdiction
AU
Classification
—
Expires
2018-03-22
Drug substance claim
No
Drug product claim
No
Assignee
Concert Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.